130 related articles for article (PubMed ID: 1580821)
1. Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide).
Ahlskog JE; Muenter MD; Bailey PA; Stevens PM
Arch Neurol; 1992 May; 49(5):560-8. PubMed ID: 1580821
[TBL] [Abstract][Full Text] [Related]
2. MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
Lieberman A; Chin L; Baumann G
Clin Neuropharmacol; 1988 Jun; 11(3):191-200. PubMed ID: 2900065
[TBL] [Abstract][Full Text] [Related]
3. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Olanow CW; Alberts MJ
Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
[No Abstract] [Full Text] [Related]
4. Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
Ahlskog JE; Muenter MD; Bailey PA; Miller PM
Clin Neuropharmacol; 1991 Jun; 14(3):214-27. PubMed ID: 1676932
[TBL] [Abstract][Full Text] [Related]
5. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients.
Earley CJ; Allen RP
Sleep; 1996 Dec; 19(10):801-10. PubMed ID: 9085489
[TBL] [Abstract][Full Text] [Related]
6. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
[TBL] [Abstract][Full Text] [Related]
7. Is stereotactic surgical treatment still necessary for Parkinson's disease in the contemporary trend of medical therapy with dopamine receptor agonist?
Amano K; Takakura K
Stereotact Funct Neurosurg; 1997; 69(1-4 Pt 2):5-18. PubMed ID: 9711730
[TBL] [Abstract][Full Text] [Related]
8. Parallel double-blind study of pergolide in Parkinson's disease.
Jankovic J; Orman J
Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
[No Abstract] [Full Text] [Related]
9. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
[TBL] [Abstract][Full Text] [Related]
10. Treatment of early Parkinson's disease: are complicated strategies justified?
Ahlskog JE
Mayo Clin Proc; 1996 Jul; 71(7):659-70. PubMed ID: 8656708
[TBL] [Abstract][Full Text] [Related]
11. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
[TBL] [Abstract][Full Text] [Related]
12. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
[TBL] [Abstract][Full Text] [Related]
13. Dopaminergic agonists in the treatment of Parkinson's disease.
Goetz CG; Diederich NJ
Neurol Clin; 1992 May; 10(2):527-40. PubMed ID: 1350052
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Parkinson's disease with pergolide: a double-blind study.
Ahlskog JE; Muenter MD
Mayo Clin Proc; 1988 Oct; 63(10):969-78. PubMed ID: 3050300
[TBL] [Abstract][Full Text] [Related]
15. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
Facca A; Sanchez-Ramos J
Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
[No Abstract] [Full Text] [Related]
16. [Pergolide: a useful agonist for the treatment of Parkinson disease].
Bonnet AM; Houeto JL
Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
[TBL] [Abstract][Full Text] [Related]
17. Pergolide: long-term use in Parkinson's disease.
Ahlskog JE; Muenter MD
Mayo Clin Proc; 1988 Oct; 63(10):979-87. PubMed ID: 3050301
[TBL] [Abstract][Full Text] [Related]
18. Double-blind trial of pergolide for Parkinson's disease.
Diamond SG; Markham CH; Treciokas LJ
Neurology; 1985 Mar; 35(3):291-5. PubMed ID: 3883232
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.
Cutler NR; Reines SA; McLean LF; Sramek JJ; Porras AG; Hand EL
Clin Pharmacokinet; 1992 Mar; 22(3):223-30. PubMed ID: 1348452
[TBL] [Abstract][Full Text] [Related]
20. New concepts in the treatment of Parkinson's disease.
Ahlskog JE; Wilkinson JM
Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
